Brief: Omega Therapeutics Submits IND Application For OTX-2002 For MYC Driven Hepatocellular Carcinoma
15/06/2022 12:15
June 15 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS ANNOUNCES SUBMISSION OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR OTX-2002, AN OMEGA EPIGENOMIC CONTROLLER,
FOR MYC DRIVEN HEPATOCELLULAR CARCINOMA
* OMEGA THERAPEUTICS INC -
* OMEGA THERAPEUTICS INC - PLANS TO INITIATE A PHASE 1
CLINICAL
TRIAL IN U.S. TO EVALUATE OTX-2002, FOLLOWING FDA CLEARANCE
Source text for Eikon: ID:nPn8yRXHpa
Further company coverage: OMGA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence